欢迎访问文传商讯!

全部新闻

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind usage in clinical practice

发布时间:2016-08-16 09:54


  • Praxbind® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa® (dabigatran)1,2
  • Praxbind® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries3
  • RE-VECTO will provide insights into the diverse types of situations in which reversal of an anticoagulant is performed in clinical practice

INGELHEIM, Germany -- (BUSINESS WIRE) --

Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).1,2 Praxbind® is approved to reverse the anticoagulant effects of Pradaxa® in rare critical care situations such as prior to emergency surgery or an urgent intervention, or in cases of life-threatening or uncontrolled bleeding.1,2 The emergency situations in which Praxbind® may be used can vary greatly, ranging from a severe car accident to a ruptured appendix. Data captured in RE-VECTO will help better understand the actual usage of the reversal agent in the clinical practice setting.4

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160815005531/en/

“Praxbind® received its first approval in the US nearly a year ago and is now widely available in the US, the EU and several other countries worldwide,” said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “By their nature, every emergency situation is unique. We have already seen this in our RE-VERSE AD™ clinical study, which could enrol all adult patients taking Pradaxa® in need of reversal, and captured a broad variety of patients and situations. RE-VECTO is an additional program designed to further our understanding of the different situations in which Praxbind® is used in clinical practice. This will ultimately help improve care for patients treated with Pradaxa® in the rare event that reversal is needed.”

The data for RE-VECTO will be captured through hospital pharmacies where Praxbind® is dispensed.5 The data collected will include anonymous information about the types of patients and situations in which Praxbind® was utilised.5 The data gathered from RE-VECTO will help shape future information and education on Praxbind® to healthcare providers and patients.

Praxbind® is the first and only specific non-vitamin K antagonist oral anticoagulant (NOAC) reversal agent approved for use in emergency situations when immediate reversal of the anticoagulant effect of Pradaxa® is required.1,2 The efficacy and safety of idarucizumab continues to be evaluated in RE-VERSE AD™ - a Phase III global clinical trial.6 It is designed to evaluate the types of patients and real-world situations healthcare professionals may see in emergency settings.7,8 The broad inclusion criteria ensure that even the most severely ill or injured patients (e.g. patients with sepsis or a severe intracranial haemorrhage), who require urgent reversal of dabigatran, may be enrolled in the study.7,8,9 Results from an interim analysis of RE-VERSE AD™ showed that idarucizumab immediately reversed the anticoagulant effect of dabigatran even in critically ill and high-risk patients in emergency situations.7

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

~ENDS~

Please click on the link below for ‘Notes to Editors and References’:

http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-launches-re-vecto-global-program

说明: http://cts.businesswire.com/ct/CT?id=bwnews&sty=20160815005531r1&sid=18029&distro=ftp

View source version on businesswire.com: http://www.businesswire.com/news/home/20160815005531/en/

 

CONTACT:

Boehringer Ingelheim GmbH
Friederike Middeke

Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
or
More information
www.boehringer-ingelheim.com

金联创 xinhua08 cacs takungpao China.com 和讯 财讯 C114.net 看商界 畅享网 中国能源网 证券之星 金融界 中金在线 天和网 中国金融网 中汽传媒 国际财经日报 中国环保网 今日亚洲新闻网 百歌新闻专线 亚洲商机 新华网能源频道 IT资讯网 中国智能卡论坛 广西物流网 品牌世家 汽车点评网 中国电子标签网 360教育在线 21世纪保险网 中国能源投资网 中国电子商业联盟 中国汽车咨询中心网 煤炭供应链 美国证券网 百奥知 CTI论坛 中国测控网 北极星电力网 能源财经网 福建之窗 智库在线 eeworld 电脑商情在线 中国电池网 赢商网 湖南信息港 赢在中国网 比邻星环保网 中国制造业门户 中国涂料在线 渝网 - 了解重庆第一站,重庆城市生活门户网站 中国云计算第一门户网站—中云网 投资界 i美股 天和财富网 太阳能信息网 爱中国能源网 世纪新能源网 中国新能源网 PVMate.com 环球外汇 橡胶网-hc360慧聪网 百年企业在线 IT168 米内 汽车工业网 第一车市汽车网 股市资讯 中国西部网 中原汽配网 科技在线 煤炭网 51招生网 教育人生 驴皮网 物流北京 51电池搜索网 大众医学 岭南医药网 5联网 股城网 BIT CNELC XXTLW 外汇通 供应链中国网 中国粘合剂网 中国储能网 家具迷 家居装修网 中華检测网 中国食品招商网 华东化工网 新疆第一汽车网 中国汽车用品交易网 大娱网 中国汽配网 山东化工网 960化工网 妈咪爱 塑胶五金网 慧聪电子网 迈点酒店网 火爆网 emcsino eetrend 绿色节能网 赤浪绿色新能源网 中国商业网 生物无忧 全球医疗器械网 贷商网 手机在线 汽车轻量化在线 中国汽车材料网 科易网 中国电子顶级开发网 中国POS机网 乐康家居 必修 国易网